CN111418833A - 作为糖尿病人群单一营养来源的低gi全营养配方粉及其制备方法 - Google Patents
作为糖尿病人群单一营养来源的低gi全营养配方粉及其制备方法 Download PDFInfo
- Publication number
- CN111418833A CN111418833A CN202010271382.7A CN202010271382A CN111418833A CN 111418833 A CN111418833 A CN 111418833A CN 202010271382 A CN202010271382 A CN 202010271382A CN 111418833 A CN111418833 A CN 111418833A
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- formula powder
- energy supply
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 66
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 40
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title description 20
- 230000002641 glycemic effect Effects 0.000 title description 2
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 30
- 235000014633 carbohydrates Nutrition 0.000 claims abstract description 30
- 235000018102 proteins Nutrition 0.000 claims abstract description 28
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 28
- 239000008280 blood Substances 0.000 claims abstract description 22
- 210000004369 blood Anatomy 0.000 claims abstract description 22
- 239000011782 vitamin Substances 0.000 claims abstract description 17
- 229940088594 vitamin Drugs 0.000 claims abstract description 16
- 229930003231 vitamin Natural products 0.000 claims abstract description 16
- 235000013343 vitamin Nutrition 0.000 claims abstract description 16
- 239000011707 mineral Substances 0.000 claims abstract description 14
- 235000010755 mineral Nutrition 0.000 claims abstract description 14
- 230000002503 metabolic effect Effects 0.000 claims abstract description 5
- 235000018343 nutrient deficiency Nutrition 0.000 claims abstract description 4
- 235000013325 dietary fiber Nutrition 0.000 claims description 47
- 235000019197 fats Nutrition 0.000 claims description 21
- 235000016709 nutrition Nutrition 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 14
- 240000000249 Morus alba Species 0.000 claims description 13
- 235000008708 Morus alba Nutrition 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 13
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 12
- 108010046377 Whey Proteins Proteins 0.000 claims description 11
- 102000007544 Whey Proteins Human genes 0.000 claims description 11
- 235000021119 whey protein Nutrition 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 229920001353 Dextrin Polymers 0.000 claims description 10
- 239000004375 Dextrin Substances 0.000 claims description 10
- 235000019425 dextrin Nutrition 0.000 claims description 10
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims description 10
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 10
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 9
- 229910052791 calcium Inorganic materials 0.000 claims description 9
- 239000008103 glucose Substances 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 239000005715 Fructose Substances 0.000 claims description 8
- 229930091371 Fructose Natural products 0.000 claims description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 8
- 229920000294 Resistant starch Polymers 0.000 claims description 8
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 8
- 235000021254 resistant starch Nutrition 0.000 claims description 8
- 229920001202 Inulin Polymers 0.000 claims description 7
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 7
- 229940029339 inulin Drugs 0.000 claims description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- 229920002774 Maltodextrin Polymers 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 5
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 claims description 5
- 239000000845 maltitol Substances 0.000 claims description 5
- 235000010449 maltitol Nutrition 0.000 claims description 5
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 5
- 229940035436 maltitol Drugs 0.000 claims description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- 230000001502 supplementing effect Effects 0.000 claims description 5
- 239000000811 xylitol Substances 0.000 claims description 5
- 235000010447 xylitol Nutrition 0.000 claims description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
- 229960002675 xylitol Drugs 0.000 claims description 5
- 229910021556 Chromium(III) chloride Inorganic materials 0.000 claims description 4
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 4
- 229960000359 chromic chloride Drugs 0.000 claims description 4
- 235000020778 linoleic acid Nutrition 0.000 claims description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 4
- 229960004488 linolenic acid Drugs 0.000 claims description 4
- 229960003966 nicotinamide Drugs 0.000 claims description 4
- 235000005152 nicotinamide Nutrition 0.000 claims description 4
- 239000011570 nicotinamide Substances 0.000 claims description 4
- 230000035764 nutrition Effects 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 229910000365 copper sulfate Inorganic materials 0.000 claims description 3
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 3
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 3
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 3
- 239000011790 ferrous sulphate Substances 0.000 claims description 3
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 229960002737 fructose Drugs 0.000 claims description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 3
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 229940099596 manganese sulfate Drugs 0.000 claims description 3
- 239000011702 manganese sulphate Substances 0.000 claims description 3
- 235000007079 manganese sulphate Nutrition 0.000 claims description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 3
- 239000011772 phylloquinone Substances 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 claims description 3
- 239000001230 potassium iodate Substances 0.000 claims description 3
- 235000006666 potassium iodate Nutrition 0.000 claims description 3
- 229940093930 potassium iodate Drugs 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 239000011781 sodium selenite Substances 0.000 claims description 3
- 235000015921 sodium selenite Nutrition 0.000 claims description 3
- 229960001471 sodium selenite Drugs 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 3
- 229960001763 zinc sulfate Drugs 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- 235000000638 D-biotin Nutrition 0.000 claims description 2
- 239000011665 D-biotin Substances 0.000 claims description 2
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 claims description 2
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 claims description 2
- 239000002211 L-ascorbic acid Substances 0.000 claims description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 2
- 239000011666 cyanocobalamin Substances 0.000 claims description 2
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 235000019198 oils Nutrition 0.000 claims description 2
- 235000019175 phylloquinone Nutrition 0.000 claims description 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 claims description 2
- 229960001898 phytomenadione Drugs 0.000 claims description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 2
- 229960000342 retinol acetate Drugs 0.000 claims description 2
- 235000019173 retinyl acetate Nutrition 0.000 claims description 2
- 239000011770 retinyl acetate Substances 0.000 claims description 2
- 235000019192 riboflavin Nutrition 0.000 claims description 2
- 229960002477 riboflavin Drugs 0.000 claims description 2
- 239000002151 riboflavin Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000020238 sunflower seed Nutrition 0.000 claims description 2
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 2
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 2
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 235000005282 vitamin D3 Nutrition 0.000 claims description 2
- 239000011647 vitamin D3 Substances 0.000 claims description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 2
- 229940021056 vitamin d3 Drugs 0.000 claims description 2
- 235000019871 vegetable fat Nutrition 0.000 claims 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 229960002104 cyanocobalamin Drugs 0.000 claims 1
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 230000035790 physiological processes and functions Effects 0.000 abstract description 6
- 239000003925 fat Substances 0.000 description 17
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 230000004060 metabolic process Effects 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 10
- 235000013305 food Nutrition 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 206010022489 Insulin Resistance Diseases 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 229910052742 iron Inorganic materials 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 208000033679 diabetic kidney disease Diseases 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 230000000291 postprandial effect Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 4
- 229930003270 Vitamin B Natural products 0.000 description 4
- -1 compound vitamin Chemical class 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 235000019156 vitamin B Nutrition 0.000 description 4
- 239000011720 vitamin B Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002366 mineral element Substances 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 235000019161 pantothenic acid Nutrition 0.000 description 3
- 239000011713 pantothenic acid Substances 0.000 description 3
- 229940055726 pantothenic acid Drugs 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 229940091258 selenium supplement Drugs 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000006479 redox reaction Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 206010010957 Copper deficiency Diseases 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000029422 Hypernatremia Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010067997 Iodine deficiency Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000009142 chromium supplementation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 235000006479 iodine deficiency Nutrition 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000009179 medical nutrition therapy Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000003863 physical function Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Pediatric Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种作为糖尿病人群单一营养来源的低GI全营养配方粉，基于营养元素的协调搭配实现低GI值并在此基础上同时兼顾蛋白质、脂肪、碳水化合物、营养素的效用比例，在限制蛋白质供能比数值低于限值的同时通过设计维生素、矿物质营养元素配比以纠正糖尿病人群因代谢紊乱导致的营养素缺乏。本发明研制的全营养配方粉能够提供糖尿病人维持正常生理机能所需的能量以及营养素，其蛋白质、脂肪、碳水化合物具有恰当的比例，能够更好的帮助糖尿病人在特殊身体状况下的血糖控制。
Description
技术领域
本发明涉及营养制品-乳制品相关技术领域，尤其涉及特殊医学用途配方乳制品及其制备。
背景技术
国际糖尿病联盟2019年发布的最新数据显示，全球有4.63亿成人糖尿病患者，而且日益增加，如不加以控制，到2045年将会高达7亿。糖尿病危害严重，具有致残致死性。据统计，2019年全球约有420万人因糖尿病及其并发症死亡，占总死亡人数的11.3％。
目前糖尿病暂不能根治，只能通过运动、药物、饮食等各种手段加以控制，而医学营养治疗正是这样一种行之有效而且必需的控制手段。
发明内容
本发明要解决的技术问题是提供一种作为糖尿病人群单一营养来源的低GI全营养配方粉，能够满足糖尿病人在特殊身体状态下的营养所需，同时帮助糖尿病人进行血糖控制。
为解决上述技术问题，本发明所采取的技术方案如下。
作为糖尿病人群单一营养来源的低GI全营养配方粉，所述配方粉基于营养元素的协调搭配实现低GI值并在此基础上同时兼顾蛋白质、脂肪、碳水化合物、营养素的效用比例，在限制蛋白质供能比数值低于限值的同时通过设计维生素、矿物质营养元素配比以纠正糖尿病人群因代谢紊乱导致的营养素缺乏，进一步通过补充膳食纤维、桑叶提取物实现延缓和控制糖尿病人血糖升高。
作为本发明的一种优选技术方案，控制所述配方粉的GI值≤60，蛋白质供能比7％-20％，饱和脂肪酸供能比≤15％，多不饱和脂肪酸供能比≤15％，单不饱和脂肪酸供能比10％-25％，碳水化合物供能比30％-65％。
作为本发明的一种优选技术方案，控制所述配方粉的GI值≤55，蛋白质供能比7％-17％，饱和脂肪酸供能比≤10％，多不饱和脂肪酸供能比≤10％，单不饱和脂肪酸供能比15％-20％，碳水化合物供能比40％-60％。
作为本发明的一种优选技术方案，所述配方粉按照重量份数比还包含膳食纤维5％-11％，桑叶提取物0.1％-1％。
作为本发明的一种优选技术方案，所述蛋白质按重量比包含80％以上的乳清蛋白。
作为本发明的一种优选技术方案，在脂肪供能比当中，亚油酸供能比2.5％-9％，α-亚麻酸供能比0.5％-1.8％，其中亚油酸与α-亚麻酸的比值为5:1-15:1。
作为本发明的一种优选技术方案，所述配方粉按照重量份数比还包含复合维生素，且复合维生素按照重量份数比包含如下原料：L-抗坏血酸30.5-71.4、dl-α-醋酸生育酚11.5-27.0、醋酸视黄酯5.5-12.9、烟酰胺1.2-2.9、氰钴胺0.7-1.9、D-泛酸钙0.7-1.7、胆钙化醇0.5-1.4、D-生物素0.5-1.3、盐酸吡哆醇0.4-1.0、叶酸0.3-0.9、盐酸硫胺素0.3-0.7、核黄素0.2-0.6、植物甲萘醌0.2-0.5。
作为本发明的一种优选技术方案，所述配方粉按照重量份数比还包含复合矿物质，且复合矿物质按照重量份数比包含如下原料：氯化钾15.0-37.0、硫酸镁12.0-30.0、磷酸氢钙11.0-27.0、柠檬酸钠8.0-20.0、碳酸钙3.0-9.0、磷酸氢二钾2.0-7.0、硫酸锰1.0-3.0、氯化钠0.4-1.1、硫酸锌0.3-0.8、三氯化铬0.3-0.8、硫酸亚铁0.3-0.8、碘酸钾0.1-0.4、硫酸铜0.07-0.30、亚硒酸钠0.06-0.20。
作为本发明的一种优选技术方案，所述配方粉按照重量份数比还包含葡萄糖耐量因子三氯化铬。
作为本发明的一种优选技术方案，所述配方粉按照重量份数比包含：乳清蛋白粉100-250、植物脂肪粉140-290、菊粉0-37、抗性糊精60-130、抗性淀粉0-50、低聚异麦芽糖0-70、果糖30-100、麦芽糖醇60-125、木糖醇0-100、麦芽糊精170-300、桑叶提取物1-10、L-阿拉伯糖0-15、复合维生素3、复合矿物质34；其中，所述植物脂肪粉每份包含如下重量份的原料：中链甘油三酯粉末2-5、葵花籽油脂粉末40-70、大豆油脂粉末30-50；提供所述碳水化合物的物质包含麦芽糊精、果糖、麦芽糖醇、木糖醇、菊粉、抗性糊精、抗性淀粉、低聚异麦芽糖、L-阿拉伯糖中的2种或多种；所述膳食纤维包含可溶性膳食纤维和不溶性膳食纤维；所述可溶性膳食纤维包含菊粉、抗性糊精、低聚异麦芽糖；所述不溶性膳食纤维包含抗性淀粉；可溶性膳食纤维与不溶性膳食纤维的重量比值为5:95-100:0。
采用上述技术方案所产生的有益效果在于：本发明研制的全营养配方粉能够提供糖尿病人维持正常生理机能所需的能量以及营养素，其蛋白质、脂肪、碳水化合物具有恰当的比例，能够更好的帮助糖尿病人在特殊身体状况下的血糖控制。本发明要通过设计恰当的维生素、矿物质等营养元素配比以纠正糖尿病人因代谢紊乱导致的营养素缺乏，通过补充膳食纤维、桑叶提取物等物质来延缓糖尿病人血糖升高，达到控制血糖的目的。
具体实施方式
以下实施例详细说明了本发明。本发明所使用的各种原料及各项设备均为常规市售产品，均能够通过市场购买直接获得。
在以下实施例的描述中，为了说明而不是为了限定，提出了诸如特定系统结构、技术之类的具体细节，以便透彻理解本申请实施例。然而，本领域的技术人员应当清楚，在没有这些具体细节的其它实施例中也可以实现本申请。在其它情况中，省略对众所周知的系统、装置、电路以及方法的详细说明，以免不必要的细节妨碍本申请的描述。
应当理解，当在本申请说明书和所附权利要求书中使用时，术语“包括”指示所描述特征、整体、步骤、操作、元素和/或组件的存在，但并不排除一个或多个其它特征、整体、步骤、操作、元素、组件和/或其集合的存在或添加。
还应当理解，在本申请说明书和所附权利要求书中使用的术语“和/或”是指相关联列出的项中的一个或多个的任何组合以及所有可能组合，并且包括这些组合。
另外，在本申请说明书和所附权利要求书的描述中，术语“第一”、“第二”、“第三”等仅用于区分描述，而不能理解为指示或暗示相对重要性。
在本申请说明书中描述的参考“一个实施例”或“一些实施例”等意味着在本申请的一个或多个实施例中包括结合该实施例描述的特定特征、结构或特点。由此，在本说明书中的不同之处出现的语句“在一个实施例中”、“在一些实施例中”、“在其他一些实施例中”、“在另外一些实施例中”等不是必然都参考相同的实施例，而是意味着“一个或多个但不是所有的实施例”，除非是以其他方式另外特别强调。术语“包括”、“包含”、“具有”及它们的变形都意味着“包括但不限于”，除非是以其他方式另外特别强调。
实施例1、糖尿病全营养配方粉A及其制备
本实施例的糖尿病全营养配方粉，其组成如下：
该实例主要针对糖尿病肾病患者，其GI值≤55，蛋白质供能比＜10％，饱和脂肪酸供能比＜10％，多不饱和脂肪酸供能比＜10％，单不饱和脂肪酸供能比15％-20％，碳水化合物供能比40％-60％，膳食纤维含量7％-11％，桑叶提取物重量份为5。本实例膳食纤维是由水溶性膳食纤维和不溶性膳食纤维组成。
本实例配方粉的制备步骤包括：采用湿法制备，维生素预溶和矿物质预溶后，乳清蛋白粉、脂肪粉、碳水化合物等→配料→均质→杀菌→浓缩→喷雾干燥→流化床二次干燥→包装。
实施例2、糖尿病全营养配方粉B及其制备
一种糖尿病全营养配方粉，其组成如下：
本实例适合非糖尿病肾病患者，其GI值≤55，蛋白质、脂肪、碳水化合物比例均衡，蛋白质供能比10％-20％，饱和脂肪酸供能比＜10％，多不饱和脂肪酸供能比＜10％，单不饱和脂肪酸供能比10％-20％，碳水化合物供能比30％-60％，膳食纤维含量7％-11％，桑叶提取物重量份为10。该实例膳食纤维是由水溶性膳食纤维和不溶性膳食纤维组成。
本实施例的制备步骤包括：湿法制备，维生素预溶、矿物质预溶后，乳清蛋白粉、脂肪粉、碳水化合物等→配料→均质→杀菌→浓缩→喷雾干燥→流化床二次干燥→包装。
实施例3、糖尿病全营养配方粉C及其制备
一种糖尿病全营养配方粉，其组成如下：
本实例适合非糖尿病肾病患者，其GI值≤55，蛋白质供能比15％-20％，饱和脂肪酸供能比＜10％，多不饱和脂肪酸供能比＜10％，单不饱和脂肪酸供能比10％-20％，碳水化合物供能比30％-60％，膳食纤维含量7％-11％，桑叶提取物重量份为7.5。该实例膳食纤维是由水溶性膳食纤维和不溶性膳食纤维组成。
本实施例制备步骤：干法制备，复合维生素与乳清蛋白粉(或脂肪粉、或碳水化合物)预混后，其余原辅料→包装灭菌→进料→配料(预混)→投料→混合→包装。
实施例4、糖尿病全营养配方粉D及其制备
一种糖尿病全营养配方粉，其组成如下：
本实例适合非糖尿病肾病患者，其GI值≤55，蛋白质供能比15％-18％，饱和脂肪酸供能比＜10％，多不饱和脂肪酸供能比＜10％，单不饱和脂肪酸供能比10％-20％，碳水化合物供能比30％-60％，膳食纤维含量7％-11％，桑叶提取物重量份为10。该实例膳食纤维全部为水溶性膳食纤维。
本实施例的制备步骤包括：干法制备，复合维生素与乳清蛋白粉(或脂肪粉、或碳水化合物)预混后，其余原辅料→包装灭菌→进料→配料(预混)→投料→混合→包装。
实施例5、蛋白质的调配
在本发明中，选择合适的蛋白质来源及其添加量比例。蛋白质供能比设计值在7％-20％，种类主要为具有血糖控制功能的乳清蛋白。本发明所选用的乳清蛋白相较于其他种类蛋白，能够更好的延缓糖尿病人餐后血糖升高，增加糖尿病人胰岛素敏感性。
实施例6、脂肪的调配
选择合适的脂肪来源及其添加量比例。总脂肪的供能比设计在20％-35％。其中饱和脂肪酸供能比≤10％，单不饱和脂肪酸供能比10％-20％，多不饱和脂肪酸供能比≤10％。本发明所选用的饱和脂肪酸由中链甘油三酯粉末提供。中链甘油三酯通过门静脉直接转运到肝脏，不影响葡萄糖和胰岛素的含量。中链甘油三酯还能提高其它营养物质的吸收,如矿物质、必需脂肪酸。本发明所选用的单不饱和脂肪酸主要由葵花籽油脂粉末提供。本发明所选用的多不饱和脂肪酸主要由大豆油脂粉末提供。多不饱和脂肪酸中的亚油酸和α-亚麻酸为必需脂肪酸。亚油酸供能比2.5％-9％，α-亚麻酸供能比0.5％-2％，其中亚油酸与α-亚麻酸的比值为5:1-15:1。
实施例7、碳水化合的调配
选择合适的碳水化合物来源及添加量比例。碳水化合物供能比为30％-60％。提供碳水化合物的主要物质为麦芽糊精、果糖、麦芽糖醇、木糖醇、菊粉、抗性糊精、抗性淀粉、低聚异麦芽糖、L-阿拉伯糖中的2种或者多种。本发明所选用的麦芽糊精为MD10型，其DE值＜11％。本发明所选用的果糖，为低GI食品，其GI值为23。果糖的代谢并不依赖胰岛素，并且代谢速度比葡萄糖慢，适量的果糖可降低餐后血糖。本发明所选用的糖醇热量值为10KJ/g，有助于维持血糖稳定，减少胰岛素分泌。其中麦芽糖醇GI值为35，木糖醇GI值为17.24±7.6，均为低GI食品。
实施例8、膳食纤维的调配
本发明选用了多种膳食纤维，总膳食纤维含量在5％-11％。其中以可溶性膳食纤维为主，可添加或不添加不溶性膳食纤维。可溶性膳食纤维在胃肠道内充分接触水和葡萄糖后会形胶体，粘度增加从而减缓糖的吸收。不溶性膳食纤维在胃肠道内吸水形成网状结构，避免食物与消化液充分接触，减缓淀粉类食物消化吸收。
本发明所选用的可溶性膳食纤维如菊粉。菊粉为新食品原料，低GI值食品，其GI值仅为2，并且可以改善胰岛素敏感性。本发明所选用的可溶性膳食纤维如抗性糊精。抗性糊精为低GI值食品，其GI值仅为5。抗性糊精能够延缓葡萄糖的吸收，抑制血糖值上升。而且，抗性糊精的耐受量很高，即使每天吃90g，也不会产生腹泻腹胀等现象。
本发明所选用的可溶性膳食纤维如低聚异麦芽糖。低聚异麦芽糖是一种非消化低聚糖，具有水溶性膳食纤维的功能，能够降低空腹血糖及餐后血糖。本发明所选用的不溶性膳食纤维如抗性淀粉。抗性淀粉是一种不能被人体消化酶所消化的碳水化合物，具有不溶性膳食纤维的功能，能够降低空腹血糖及餐后血糖。
本发明所选用的桑叶提取物，含有生物活性物质1-脱氧野尻霉素。该生物活性物质是一种α-葡萄糖苷酶抑制剂，能够抑制α-葡萄糖苷酶对蔗糖、碳水化合物酶解成单糖的作用，减少人体对糖的吸收，减少餐后血糖升高。
实施例9、维生素的调配
本发明含有维生素A、维生素D、维生素E、维生素K1、维生素B1、维生素B2、维生素B6、维生素B12、烟酸(烟酰胺)、叶酸、泛酸、维生素C、生物素等维生素。作为全营养配方食品，维生素的作用一是维持人体的正常生理功能，二是补充糖尿病人由于代谢紊乱引起的维生素缺乏。
本发明所选用的维生素A，是一种有效的抗氧化和清除自由基的物质，可保护机体免受过氧化物的损伤。维生素A有助于维持暗视力以及皮肤和粘膜健康。本发明所选用的维生素D，是维持血钙和磷水平的重要物质，对人体实现骨骼钙化，肌肉收缩、神经传导等功能所必需的的物质。人体血液中维生素D有助于改善胰岛素抵抗。本发明所选用的维生素E，具有强大的抗氧化性，可通过清除自由基、增强谷胱甘肽过氧化物酶等抗氧化酶类活性的作用，改善机体对胰岛素的敏感性，有利于血糖的控制。本发明所选用的维生素K1，是肝脏中凝血酶原和其他凝血因子合成必不可少的物质，其缺乏可以导致致命性大出血。本发明所选用的维生素B1，能够维持人体神经系统的正常生理功能，是抗脚气因子和抗神经炎因子，其缺乏会引起脚气病。医学上常用于治疗糖尿病神经病变。本发明所选用的维生素B2，参与体内的氧化还原反应，以及维持体内还原型谷胱甘肽的水平，其缺乏容易引起各类皮肤炎症，还可继发缺铁性贫血。本发明所选用的维生素B6，参与体内的氨基酸、脂肪以及糖原的代谢，参与神经系统中的多种酶促反应，间接影响神经系统的生理功能。本发明所选用的维生素B12，参与细胞的核酸代谢，是造血功能必需的，缺乏可导致恶性贫血，医学常用于治疗糖尿病神经病变。本发明所选用的烟酰胺，参与机体中的多种氧化还原反应，作为葡萄糖耐量因子的组分，可促进胰岛素反应，促使葡萄糖转化为脂肪。本发明所选用的泛酸，参与体内蛋白质、脂肪、碳水化合物的代谢，其缺乏会出现足部麻木和灼热感，还可引起胰岛素敏感性降低。本发明所选用的维生素C，具有强大的抗氧化性，能够促进铁吸收、提高机体免疫力。给糖尿病人补充足够的维生素C，能够预防糖尿病神经和血管病变的发生和发展。本发明所选用的生物素，在氨基酸、脂肪、碳水化合物代谢中起着重要作用，在胰岛素分泌，调节血糖和免疫等方面具有积极意义。
实施例10、矿物质的调配
本发明含有钠、钾、铜、镁、铁、锌、锰、钙、磷、碘、氯、硒、铬等矿物元素。糖尿病人由于代谢障碍，很容易引起矿物元素代谢紊乱。这些矿物元素本身也对胰岛素的合成以及能量代谢起着重要作用。
本发明所选用的钠，主要来源于氯化钠及柠檬酸钠。钠具有维持细胞外渗透压的重要作用。其缺乏会出现疲倦、呕吐、血压降低等症状，严重者会导致休克甚至急性肾功能衰竭而致命。其过量会引起高血压、高钠血症，增加高血压、心血管疾病和肿瘤发生的危险性。本发明所选用的钾，主要来源于氯化钾和磷酸氢二钾。钾参与蛋白质和糖代谢，维持细胞内渗透压，起到调节酸碱平衡的作用。还有维持神经肌肉应激性和维持心肌正常功能的作用。本发明所选用的铜，主要来源于硫酸铜。铜参与铜蛋白和多种酶的构成，具有维持正常造血功能，维持中枢神经系统健康等功能，缺乏可导致缺铜性贫血，损伤心血管及中枢神经等。本发明所选用的镁，主要来源于硫酸镁。镁是体内多种酶包括糖代谢酶合成的辅助因子。镁缺乏可能加重胰岛素抵抗、糖耐量异常和高血压。本发明所选用的铁，主要来源于硫酸亚铁。铁参与血红蛋白的合成，参与体内氧气的运送和组织呼吸过程。补充铁应适量，过量的铁也会引起或加剧糖尿病及其并发症。本发明所选用的锌，主要来源于硫酸锌。锌与胰岛素的合成、分泌、贮存、降解、生物活性有关，缺锌会导致胰岛素合成减少。本发明所选用的锰，主要来源于硫酸锰。锰参与骨骼的形成，氨基酸、胆固醇和碳水化合物的代谢，具有维持脑功能和神经递质的合成与代谢等功能。本发明所选用的钙，主要来源于碳酸钙和磷酸氢钙。钙是骨骼和牙齿的主要成分，能够维持机体的多种生理功能。钙缺乏可能对血糖产生不良影响，联合补充钙与维生素D，有助于改善糖代谢，提高胰岛素敏感性。本发明所选用的磷，主要来源于磷酸氢钙。磷是骨骼和牙齿的主要成分，参与机体多种代谢，维持生物膜的正常结构。磷代谢异常会引起骨代谢病变，本发明所选用的碘，主要来源于碘酸钾。碘参与甲状腺激素的合成，能够促进生长发育，调节新陈代谢。碘缺乏可引起甲状腺肿大。本发明所含有的氯，主要是补充其他营养元素时，一同带到产品中的。氯是维持电解质平衡的必需成分，也是胃液的必需成分，参与血液二氧化碳的运输。本发明所选用的硒，主要来源于亚硒酸钠。硒参与谷胱甘肽过氧化酶的构成，而谷胱甘肽过氧化酶可降低机体内的脂质过氧化反应，保护多个脏器免受自由基损伤。本发明所选用的铬，主要来源于氯化铬。铬被称为葡萄糖耐量因子，适量补充铬有利于改善糖代谢。
综上实施例可见，本发明是为满足糖尿病人对膳食以及营养素的特殊需要，专门加工制备而成的一种特殊食品，可作为单一营养来源满足糖尿病人的营养需求。本发明的特征在于其GI值≤55；蛋白质供能比7％-20％，主要由乳清蛋白粉提供；总脂肪供能比20％-35％,其中饱和脂肪酸供能比≤10％，单不饱和脂肪酸供能比10％-20％，多不饱和脂肪酸供能比≤10％；碳水化合物的供能比为30％-60％；膳食纤维的含量5％-11％，可为水溶性膳食纤维，添加或不添加不溶性膳食纤维；低钠含量为0.11％-0.36％；特别添加桑叶提取物，重量份为5-10。本发明可以为糖尿病人提供能量且供能比合理，提供维持身体机能所必需的维生素和矿物质，并且能够帮助糖尿病人合理有效的进行血糖控制。
以上所述实施例仅用以说明本发明的技术方案，而非对其限制；尽管参照前述实施例对本发明进行了详细的说明，本领域的普通技术人员应当理解：其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分技术特征进行等同替换；而这些修改或者替换，并不使相应技术方案的本质脱离本发明各实施例技术方案的精神和范围，均应包含在本发明的保护范围之内。
Claims (10)
1.作为糖尿病人群单一营养来源的低GI全营养配方粉，其特征在于：所述配方粉基于营养元素的协调搭配实现低GI值并在此基础上同时兼顾蛋白质、脂肪、碳水化合物、营养素的效用比例，在限制蛋白质供能比数值低于限值的同时通过设计维生素、矿物质营养元素配比以纠正糖尿病人群因代谢紊乱导致的营养素缺乏，进一步通过补充膳食纤维、桑叶提取物实现延缓和控制糖尿病人血糖升高。
2.根据权利要求1所述的作为糖尿病人群单一营养来源的低GI全营养配方粉，其特征在于：控制所述配方粉的GI值≤60，蛋白质供能比7％-20％，饱和脂肪酸供能比≤15％，多不饱和脂肪酸供能比≤15％，单不饱和脂肪酸供能比10％-25％，碳水化合物供能比30％-65％。
3.根据权利要求1所述的作为糖尿病人群单一营养来源的低GI全营养配方粉，其特征在于：控制所述配方粉的GI值≤55，蛋白质供能比7％-17％，饱和脂肪酸供能比≤10％，多不饱和脂肪酸供能比≤10％，单不饱和脂肪酸供能比15％-20％，碳水化合物供能比40％-60％。
4.根据权利要求1所述的作为糖尿病人群单一营养来源的低GI全营养配方粉，其特征在于：所述配方粉按照重量份数比还包含膳食纤维5％-11％，桑叶提取物0.1％-1％。
5.根据权利要求1所述的作为糖尿病人群单一营养来源的低GI全营养配方粉，其特征在于：所述蛋白质按重量比包含80％以上的乳清蛋白。
6.根据权利要求1所述的作为糖尿病人群单一营养来源的低GI全营养配方粉，其特征在于：在脂肪供能比当中，亚油酸供能比2.5％-9％，α-亚麻酸供能比0.5％-1.8％，其中亚油酸与α-亚麻酸的比值为5:1-15:1。
7.根据权利要求1所述的作为糖尿病人群单一营养来源的低GI全营养配方粉，其特征在于：所述配方粉按照重量份数比还包含复合维生素，且复合维生素按照重量份数比包含如下原料：L-抗坏血酸30.5-71.4、dl-α-醋酸生育酚11.5-27.0、醋酸视黄酯5.5-12.9、烟酰胺1.2-2.9、氰钴胺0.7-1.9、D-泛酸钙0.7-1.7、胆钙化醇0.5-1.4、D-生物素0.5-1.3、盐酸吡哆醇0.4-1.0、叶酸0.3-0.9、盐酸硫胺素0.3-0.7、核黄素0.2-0.6、植物甲萘醌0.2-0.5。
8.根据权利要求1所述的作为糖尿病人群单一营养来源的低GI全营养配方粉，其特征在于：所述配方粉按照重量份数比还包含复合矿物质，且复合矿物质按照重量份数比包含如下原料：氯化钾15.0-37.0、硫酸镁12.0-30.0、磷酸氢钙11.0-27.0、柠檬酸钠8.0-20.0、碳酸钙3.0-9.0、磷酸氢二钾2.0-7.0、硫酸锰1.0-3.0、氯化钠0.4-1.1、硫酸锌0.3-0.8、三氯化铬0.3-0.8、硫酸亚铁0.3-0.8、碘酸钾0.1-0.4、硫酸铜0.07-0.30、亚硒酸钠0.06-0.20。
9.根据权利要求1所述的作为糖尿病人群单一营养来源的低GI全营养配方粉，其特征在于：所述配方粉按照重量份数比还包含葡萄糖耐量因子三氯化铬。
10.根据权利要求1所述的作为糖尿病人群单一营养来源的低GI全营养配方粉，其特征在于：所述配方粉按照重量份数比包含：乳清蛋白粉100-250、植物脂肪粉140-290、菊粉0-37、抗性糊精60-130、抗性淀粉0-50、低聚异麦芽糖0-70、果糖30-100、麦芽糖醇60-125、木糖醇0-100、麦芽糊精170-300、桑叶提取物1-10、L-阿拉伯糖0-15、复合维生素3、复合矿物质34；其中，所述植物脂肪粉每份包含如下重量份的原料：中链甘油三酯粉末2-5、葵花籽油脂粉末40-70、大豆油脂粉末30-50；提供所述碳水化合物的物质包含麦芽糊精、果糖、麦芽糖醇、木糖醇、菊粉、抗性糊精、抗性淀粉、低聚异麦芽糖、L-阿拉伯糖中的2种或多种；所述膳食纤维包含可溶性膳食纤维和不溶性膳食纤维；所述可溶性膳食纤维包含菊粉、抗性糊精、低聚异麦芽糖；所述不溶性膳食纤维包含抗性淀粉；可溶性膳食纤维与不溶性膳食纤维的重量比值为5:95-100:0。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010271382.7A CN111418833A (zh) | 2020-04-08 | 2020-04-08 | 作为糖尿病人群单一营养来源的低gi全营养配方粉及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010271382.7A CN111418833A (zh) | 2020-04-08 | 2020-04-08 | 作为糖尿病人群单一营养来源的低gi全营养配方粉及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111418833A true CN111418833A (zh) | 2020-07-17 |
Family
ID=71555981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010271382.7A Pending CN111418833A (zh) | 2020-04-08 | 2020-04-08 | 作为糖尿病人群单一营养来源的低gi全营养配方粉及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111418833A (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112273440A (zh) * | 2020-09-16 | 2021-01-29 | 内蒙古欧世蒙牛乳制品有限责任公司 | 一种具有平衡血糖功效的低gi组合物和低gi奶粉 |
| CN112715945A (zh) * | 2020-12-31 | 2021-04-30 | 广州景腾医疗科技有限公司 | 一种低gi型匀浆膳 |
| CN112841637A (zh) * | 2021-03-30 | 2021-05-28 | 江南大学 | 一种辅助降血糖的营养素组合物 |
| CN117243380A (zh) * | 2023-09-05 | 2023-12-19 | 逢时(青岛)海洋科技有限公司 | 一种降血糖复方组合物、制备方法及其应用 |
| CN117643375A (zh) * | 2023-12-21 | 2024-03-05 | 中山大学孙逸仙纪念医院 | 一种适合t2dm强化治疗后维持的低gl膳食配方及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107279296A (zh) * | 2017-06-16 | 2017-10-24 | 杭州千岛湖康诺邦健康产品有限公司 | 一种适合糖尿病的配方食品及其制备方法 |
| CN108095085A (zh) * | 2017-12-25 | 2018-06-01 | 陕西三正医用营养有限公司 | 一种糖尿病特定全营养特殊医学用途配方食品及其制备方法 |
| CN108208802A (zh) * | 2017-12-31 | 2018-06-29 | 西安凯伦生物科技有限公司 | 一种适合糖尿病患者食用的特殊膳食及其制备方法 |
-
2020
- 2020-04-08 CN CN202010271382.7A patent/CN111418833A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107279296A (zh) * | 2017-06-16 | 2017-10-24 | 杭州千岛湖康诺邦健康产品有限公司 | 一种适合糖尿病的配方食品及其制备方法 |
| CN108095085A (zh) * | 2017-12-25 | 2018-06-01 | 陕西三正医用营养有限公司 | 一种糖尿病特定全营养特殊医学用途配方食品及其制备方法 |
| CN108208802A (zh) * | 2017-12-31 | 2018-06-29 | 西安凯伦生物科技有限公司 | 一种适合糖尿病患者食用的特殊膳食及其制备方法 |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112273440A (zh) * | 2020-09-16 | 2021-01-29 | 内蒙古欧世蒙牛乳制品有限责任公司 | 一种具有平衡血糖功效的低gi组合物和低gi奶粉 |
| CN112715945A (zh) * | 2020-12-31 | 2021-04-30 | 广州景腾医疗科技有限公司 | 一种低gi型匀浆膳 |
| CN112841637A (zh) * | 2021-03-30 | 2021-05-28 | 江南大学 | 一种辅助降血糖的营养素组合物 |
| CN117243380A (zh) * | 2023-09-05 | 2023-12-19 | 逢时(青岛)海洋科技有限公司 | 一种降血糖复方组合物、制备方法及其应用 |
| CN117643375A (zh) * | 2023-12-21 | 2024-03-05 | 中山大学孙逸仙纪念医院 | 一种适合t2dm强化治疗后维持的低gl膳食配方及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111418833A (zh) | 作为糖尿病人群单一营养来源的低gi全营养配方粉及其制备方法 | |
| EP0721742B1 (en) | Nutrition for elderly patients | |
| CN1097436C (zh) | 糖尿病患者的医疗食品 | |
| CN101027074B (zh) | 复合肠内营养组合物 | |
| CN104286849A (zh) | 一种糖尿病专用型肠内营养多聚合剂 | |
| EP2100604B1 (en) | Medium chain dicarboxylic acids and their derivates and metabolic disorders | |
| CN111011691A (zh) | 一种高蛋白高纤维固体饮料 | |
| CN102113648A (zh) | 一种适合“五高”代谢综合症人群的特膳面条及其制备方法 | |
| CN103431392B (zh) | 一种供糖尿病患者食用的复合海洋特膳食品 | |
| CN112493318A (zh) | 一种专用于三周岁以上儿童的全营养奶粉及其制备方法 | |
| CN108391811A (zh) | 一种肿瘤全营养配方食品及其应用 | |
| CN110742267B (zh) | 一种炎性肠病全营养配方食品 | |
| ZA200501340B (en) | Nutritional supplement for children | |
| CN115251373A (zh) | 一种用于控制体重的特殊膳食食品、制备工艺及其应用 | |
| CA2505103A1 (en) | Nutritional supplement for adults | |
| CN108703376A (zh) | 一种短肽型肠内营养多聚合剂 | |
| CN106473149A (zh) | 一种多维多矿组合物 | |
| CN101642468A (zh) | 用于降低血糖和血脂的药物组合物 | |
| AU2004241884A1 (en) | A method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein | |
| WO2008140064A1 (ja) | 生活習慣病の予防および改善のための栄養組成物 | |
| CN104982768B (zh) | 一种适合肾病病人能量补充的果冻及其制作方法 | |
| CN111938142A (zh) | 全营养品及制作方法 | |
| CN117678742A (zh) | 营养制剂及其应用 | |
| CN117204572A (zh) | 一种蛋白补充剂及其制备方法和应用 | |
| CN117941826A (zh) | 一种特殊医学用途全营养蛋白粉及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200717 |
|
| RJ01 | Rejection of invention patent application after publication |